PMID- 29288176
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 7
IP  - 12
DP  - 2017 Dec 28
TI  - Do biological disease-modifying antirheumatic drugs reduce the spinal fracture 
      risk related to ankylosing spondylitis? A longitudinal multiregistry matched 
      cohort study.
PG  - e016548
LID - 10.1136/bmjopen-2017-016548 [doi]
LID - e016548
AB  - OBJECTIVES: Ankylosing spondylitis (AS) is associated with an increased spinal 
      fracture risk due to the loss of elasticity in spinal motion segments. With the 
      introduction of biological disease-modifying antirheumatic drug (bDMARD) 
      treatment for AS, the individual course of the disease has been ameliorated. This 
      study aims to examine the association of bDMARD treatment and risk of spinal 
      fracture. DESIGN: Longitudinal population-based multiregistry observational 
      matched cohort study. SETTING: Swedish Patient Registry 1987-2014 and Swedish 
      Prescribed Drugs Registry 2005-2014. PARTICIPANTS: Included were patients >/=18 
      years of age receiving treatment at a healthcare facility for the primary 
      diagnosis of AS. About 1352 patients received more than one prescription of 
      bDMARD from 2005 to 2014. An untreated control group was created by propensity 
      score matching for age, sex, comorbidity, antirheumatic prescriptions and years 
      with AS (n=1352). MAIN OUTCOME MEASURES: Spinal fracture-free survival. RESULTS: 
      No bDMARD treatment-related effect on spinal fracture-free survival was observed 
      in the matched cohorts. Male gender (HR=2.54, 95% CI 1.48 to 4.36) and Charlson 
      Comorbidity Index score (HR=3.02, 95% CI 1.59 to 5.75) contributed significantly 
      to spinal fracture risk. CONCLUSION: bDMARD had no medium-term effect on the 
      spinal fracture-free survival in patients with AS. TRIAL REGISTRATION NUMBER: 
      NCT02840695; Post-results.
CI  - (c) Article author(s) (or their employer(s) unless otherwise stated in the text of 
      the article) 2017. All rights reserved. No commercial use is permitted unless 
      otherwise expressly granted.
FAU - Robinson, Yohan
AU  - Robinson Y
AUID- ORCID: 0000-0002-2724-6372
AD  - Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden.
FAU - Olerud, Claes
AU  - Olerud C
AD  - Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden.
FAU - Willander, Johan
AU  - Willander J
AD  - Department of Psychology, Gavle University College, Gavle, Sweden.
LA  - eng
SI  - ClinicalTrials.gov/NCT02840695
SI  - ClinicalTrials.gov/NCT02840695
PT  - Journal Article
DEP - 20171228
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
PMC - PMC5770921
OTO - NOTNLM
OT  - ankylosing spondylitis
OT  - fracture
OT  - rheumatology
OT  - spine
COIS- Competing interests: YR and CO have been paid for developing and delivering 
      educational presentations for Medtronic and DePuy Synthes.
EDAT- 2017/12/31 06:00
MHDA- 2017/12/31 06:01
PMCR- 2017/12/28
CRDT- 2017/12/31 06:00
PHST- 2017/12/31 06:00 [entrez]
PHST- 2017/12/31 06:00 [pubmed]
PHST- 2017/12/31 06:01 [medline]
PHST- 2017/12/28 00:00 [pmc-release]
AID - bmjopen-2017-016548 [pii]
AID - 10.1136/bmjopen-2017-016548 [doi]
PST - epublish
SO  - BMJ Open. 2017 Dec 28;7(12):e016548. doi: 10.1136/bmjopen-2017-016548.